Sarepta Therapeutics (SRPT) Non-Current Debt (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Non-Current Debt of $838.2 million for Q1 2026, down 26.37% year-over-year from $1.1 billion in Q1 2025, and up 1.11% quarter-over-quarter from $829.0 million in Q4 2025.
Sarepta Therapeutics (SRPT) Non-Current Debt (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Non-Current Debt history runs 17 years deep, the most recent figure standing at $838.2 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 26.37% year-over-year to $838.2 million; the TTM figure through Mar 2026 stood at $838.2 million (down 26.37% YoY), while the FY2025 annual figure was $829.0 million, down 27.1% from the prior year.
- Non-Current Debt for Q1 2026 stood at $838.2 million, up from $829.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $1.5 billion in Q4 2022, with the low at $829.0 million in Q4 2025.
- The 5-year median for Non-Current Debt is $1.1 billion (2025), against an average of $1.2 billion.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt surged 173.97% in 2022, then retreated 27.1% in 2025.
- Sarepta Therapeutics' Non-Current Debt stood at $1.5 billion in 2022, then decreased by 19.83% to $1.2 billion in 2023, then declined by 8.15% to $1.1 billion in 2024, then dropped by 27.1% to $829.0 million in 2025, then gained by 1.11% to $838.2 million in 2026.
- Business Quant data shows SRPT's Non-Current Debt at $838.2 million in Q1 2026, $829.0 million in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 847.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 847.62 Mn |
| Mar 31, 2026 | 838.16 Mn |
| Dec 31, 2025 | 828.97 Mn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 1.14 Bn |
| Mar 31, 2025 | 1.14 Bn |
| Dec 31, 2024 | 1.14 Bn |
| Sep 30, 2024 | 1.14 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Mar 31, 2024 | 1.24 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.24 Bn |
| Mar 31, 2023 | 1.23 Bn |
| Dec 31, 2022 | 1.54 Bn |
| Sep 30, 2022 | 1.54 Bn |
| Jun 30, 2022 | 1.10 Bn |
| Mar 31, 2022 | 1.10 Bn |
| Dec 31, 2021 | 563.67 Mn |
| Sep 30, 2021 | 1.09 Bn |